MET and ovarian carcinoma: To examine whether miR‐181 downregulation was accompanied by MET upregulation in ovarian cancer cells with high CD24 expression, the other 6 clones derived from the ovarian cancer patient (3 clones for CD24‐low and 3 for CD24‐high) were additionally analysed.